Targacept-Catalyst merger in review as Pfizer exits Factor VII collaboration
Pfizer’s termination of a partnership to develop Factor VIIa products may have implications in the recently announced merger of Catalyst Biosciences with Targacept.
Pfizer’s termination of a partnership to develop Factor VIIa products may have implications in the recently announced merger of Catalyst Biosciences with Targacept.
An Ebola viral vector vaccine in development by Profectus BioSciences works in monkeys against the virus strain currently infecting humans in West Africa.
Colorado has become the latest US state to legislate substitution of interchangeable biosimilars.
Watson-Marlow has shelled out £7m ($10m) to add high purity equipment company Asepco to bolster its bioprocessing offerings.